Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 m...
Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Guiding treatment decisions through the use of molecular profiling in breast can...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Managing metastatic breast cancer and beyond using PARP inhibitors
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Updates in metastatic and early-stage breast cancer
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
PARP inhibitors in metastatic breast cancer: Where are we now?
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus riboc...
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC...
Prof Hope Rugo - University of California, San Francisco, USA
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )
10 Jun 2019
Breast cancer highlights from ASCO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast canc...
Dr Zahi Mitri - OHSU Hospital, Portland, USA
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )
6 Jun 2019
Better education about breast cancer treatment in Africa
Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International, Acc...
Better education about breast cancer treatment in Africa ( Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International, Accra, Ghana )
5 Jun 2019
Genomic trends across the African Diaspora for breast cancer
Prof Melissa B Davis - Weill Cornell Medical College, New York, USA
Genomic trends across the African Diaspora for breast cancer ( Prof Melissa B Davis - Weill Cornell Medical College, New York, USA )
5 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019